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At a Glance Commentary
Scientific Knowledge on the Subject
Neutrophils are the first line of defence against bacterial infection and formation of 
neutrophil extracellular traps (NETs) is an important protective mechanism. However, NETs 
can also cause harm by exposing cytotoxic histones and promoting intravascular coagulation. 
Although increasingly considered as important therapeutic targets, there is currently no robust 
measure of NETs formation to inform clinical care and enable precision medicine in patients 
on the intensive care unit (ICU). 
What This Study Adds to the Field
We have established a novel assay by incubating patient plasma with neutrophils to directly 
induce and measure NETs-formation. This is different from currently available assays, which 
primarily detect NETs-breakdown products. Using this assay in a prospective cohort of 341 
ICU patients, we found that the degree of NETs formation is significantly associated with 
disease severity and independently predicted development of disseminated intravascular 
coagulation (DIC) and mortality. This assay also enabled identification of interleukin-8 (IL-8) 
as a major factor that drives NETosis through mitogen-activated protein kinase (MAPK) 
pathway activation. Inhibiting IL-8 or MAPK significantly reduced NETs formation. 
Therefore, this assay can inform on the in vivo capacity for NETs formation and its inducing 
factors to enable improved therapeutic targeting strategies for ICU patients.
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Abstract
Rational: Neutrophil extracellular traps (NETs) are important in the host defence against 
infection, but also promote intravascular coagulation and multi-organ failure (MOF) in 
animal models. Its clinical significance remains unclear and available assays for patient care 
lack specificity and reliability. 
Objectives: To establish a novel assay and test its clinical significance 
Methods: A prospective cohort of 341 consecutive adult ICU patients was recruited. The 
NETs-forming capacity of ICU admission blood samples was semi-quantified by directly 
incubating patient plasma with isolated neutrophils ex vivo. The association of NETs–
forming capacity with sequential organ failure assessment (SOFA) scores, disseminated 
intravascular coagulation (DIC) and 28-day mortality were analysed and compared with 
available NETs assays.
Measurements and Main Results: Using the novel assay, we could stratify ICU patients 
into 4 groups with absent (22.0%), mild (49.9%), moderate (14.4%) and strong (13.8%) 
NETs formation, respectively. Strong NETs formation was predominantly found in sepsis (P 
<0.0001). Adjusted by APACHE II, multivariate regression showed that the degree of NETs 
formation could independently predict DIC and mortality whereas other NETs assays, e.g. 
cell-free DNA, myeloperoxidase and myeloperoxidase-DNA complexes, could not. IL-8 
levels were found to be strongly associated with NETs formation and inhibiting IL-8 
significantly attenuated NETosis. MAPK activation by IL-8 has been identified as a major 
pathway of NETs formation in patients.
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Conclusions: This assay directly measures the NETs-forming capacity in patient plasma. 
This could guide clinical management and enable identification of NETs-inducing factors in 
individual patients for targeted treatment and personalised ICU medicine. 
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Introduction
Morbidity and mortality rates in critically ill patients remain high despite significant advances 
in intensive care unit (ICU) management. Sepsis is a major driver of poor outcome and as 
sepsis definitions have shifted towards infection-triggered organ dysfunction (1), the 
pathophysiology that underlies progressive organ failure requires further elucidation (2). The 
microcirculation plays a key role in the development of organ dysfunction and is particularly 
vulnerable to the interactions between inflammation, coagulation and innate immune 
activation (3). Aberration of this process can cause ‘immunothrombosis’ (4) and promote 
development of disseminated intravascular coagulation (DIC) to impair microcirculation.
The role of neutrophils in immunothrombosis is increasingly recognised (4). Activated 
neutrophils can expel nuclear chromatin to form NETs (5, 6) in response to different 
pathogens (7-12), bacterial toxins (12, 13), cytokines (12, 14-17), histones (18) and activated 
platelets (19, 20). Mechanistically, NETs are formed through reactive oxygen species 
generation via the mitogen-activated protein kinase (MAPK) pathway that specifically 
includes mitogen-activated protein kinase kinase (MEK–extracellular-signal-regulated kinase 
(ERK)) signalling (21), to trigger myeloperoxidase (MPO)-mediated activation of neutrophil 
elastase (NE) and protein-arginine deiminase type 4 (PAD4) activation. The resultant histone 
citrullination leads to chromatin decondensation and the expulsion of extracellular DNA 
decorated with antimicrobial enzymes (NE and MPO) and histones (22). NETs can trap and 
kill bacteria to form a first line defence against infection. However, excessive NETs 
formation facilitates immunothrombosis and even DIC (23-28), to damage microcirculation 
and contribute to organ failure (19, 29, 30). NETs have been recognised as therapeutic 
targets, particularly in critical illnesses (19, 31, 32) and monitoring the levels of NETs 
formation in real time may benefit these patients in clinical practice.  
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Although NETs can be induced and monitored in vitro and in animal models (12, 33), this has 
been difficult to quantify in clinical settings. Currently, assays to monitor NETs formation are 
limited to invasive organ biopsy observations or through indirect measures, such as 
circulating cell-free DNA (cfDNA), nucleosomes, citrullinated-histone (Cit-H3), MPO, Cit-
H3-DNA or MPO-DNA complexes (34-36). The clinical potential of these surrogate markers 
of NETs formation have been highlighted for critical illness (26, 37, 38) but do not correlate 
with disease severity (34-36). Furthermore, their circulating levels are unstable and subject to 
enzymatic degradation (18, 39-41). Therefore, a more reliable assay is urgently required.  In 
this study, we have developed an assay to directly determine the NETs-forming capacity of 
patient plasma and its clinical usage has also been evaluated in a prospective cohort of ICU 
patients. 
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Methods (413)
Study Design and participants
A prospective cohort of adult patients admitted to a general adult ICU at the Royal Liverpool 
University Hospital (RLUH), United Kingdom, between June 2009 and June 2013 was 
assessed. Patients were enrolled in accordance with the protocol approved by the NRES 
Committee North West - Greater Manchester West and Liverpool Central (Ref: 07/H1009/64 
and 13/NW/0089). Written informed consent was obtained for all participants, and daily 
serial blood samples were collected over the first 96 hours of ICU admission (study duration). 
Exclusion criteria were: transfers from other ICUs, ICU re-admissions within 30 days, pre-
existing causes of neutropenia (including haematological malignancy), intravenous heparin 
treatment (42) or insufficient plasma preserved to effectively perform functional analysis 
(Figure E1). ICU admission diagnoses were verified by two independent experienced 
clinicians. Admission APACHE II, daily Sequential Organ Failure Assessment (SOFA) and 
modified SOFA scores (platelet component removed to avoid bias from thrombocytopenia) 
were recorded along with outcome measures including respiratory/cardiovascular support 
days, length of ICU stay (LOS) and 28-day mortality (from ICU admission). Sepsis was 
defined using the ACCP/SCCM 2001 International Sepsis Definition (1). 
DIC scoring was performed daily for the first 96 hours of ICU stay, using criteria defined by 
the International Society for Thrombosis and Haemostasis (ISTH).(43) DIC was diagnosed 
when a cumulative score of ≥5 was reached from: platelet (≥100x103/µl=0; <100 x103/µl=1; 
<50 x103/µl=2), fibrinogen (≥1.0 g/L= 0; <1 g/L=1), D-dimers (no increase=0; moderate 
increase=2; strong increase=3) and prolongation of prothrombin time (PT) (3 seconds=0; >3 
but < 6 seconds=1; >6 seconds=2) (43).
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Ex vivo assay of NETs-forming capacity 
Assay development was performed using a cohort of 54 sepsis patients (NHS REC ethical 
approval 13/WA/0353) admitted to the ICU at Aintree University Hospital and the RLUH. 
The capacity of patient platelet-poor-plasma to form NETs was tested by incubating patient 
or healthy control plasma (or serum, where indicated) (100 µL) with heterologous neutrophils 
(2x105) from healthy volunteers (eMethods in Supplement) or patient-specific neutrophils, 
where indicated for 4 hours in glass chamber slides (BD Biosciences) at 37°C in 5% CO2. 
After fixation (2% paraformaldehyde, Sigma-Aldrich), extracellular DNA was stained with 
10 µg/mL Propidium Iodide (PI, Sigma-Aldrich) and visualized by immunoflourescent 
microscopy (20x magnification unless specified). Quantification was performed by double-
blinded assessment of extracellular DNA release by three experienced clinical scientists and 
the average percentage was used for analysis. Degree of NETs formed was categorised into 4 
groups: absence of NETs = 0% neutrophils forming NETs per microscopic field, mild NETs 
= 1% to 25%, moderate NETs = 26% to 50%, strong NETs ≥50%, including amalgam of 
webs. For validation, plasma-induced NETs were stained with anti-human neutrophil elastase 
(NE) (SantaCruz) and anti-human MPO (Abcam) along with FITC and AF700 secondary 
antibodies. Mechanistic studies were performed using specific inhibitors of either PAD4 (Cl-
amidine (Cambridge biolabs)), IL-8 (IL-8 mAb (R&D Systems), CXCR1/2 (Reparixin 
(Dempé) or AZD5069 (AstraZeneca)) or MAPK signalling (U0126 (Sigma)). 
Clinical samples
Following ICU admission, surplus blood samples were collected daily from all patients for 
the first 96 hours, in accordance with ethically approved protocols. Measurements included 
whole blood cell counts, coagulation parameters, NETs-related markers and cytokines 
(eMethods in Supplement).
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Statistical Analysis 
Distributions of continuous variables were assessed by Q/Q plots, histograms and Shapiro-
Wilk tests. Clinical parameters were non-parametric in nature and are presented as median 
and interquartile ranges [1st, 3rd quartiles]. NETs-forming capacity was analysed in two ways: 
(a) as continuous variables (percentage NETs per microscopic field), and (b) as categorical 
groups, based on degree of NETs. Differences in medians between two (Mann Whitney U 
test) or more groups (Kruskall-Wallis test) were assessed. For cytokine analysis and 
comparator NETs assays, the NETs categories were also compared to healthy controls. Chi-
squared test was used for categorical variables (gender, ethnicity, presence/absence of ICU 
admission diagnosis, DIC and 28-day mortality) between either two or more groups.  
Correlation analysis utilised Spearman rank’s correlation test. To test whether our NETs 
assay and other NETs-related markers were independent predictors of DIC and mortality, 
multivariable analysis of crude and adjusted odds ratios were performed (with patients 
adjusted for APACHE II scores). Multivariate model construction is detailed in eMethods in 
supplement (Table E1). Receiver Operating Characteristic (ROC) curves assessed the 
performance of the different parameters (using continuous variables on ICU admission) for 
predicting DIC and mortality. Comparison of ROC curves were performed using Delong’s 
test using MedCalc software. All other analyses were performed using SPSS (version 22) 
statistical software. P value (two-tailed) <0.05 was considered statistically significant.
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Results
NETs can be directly induced by incubating neutrophils with plasma or sera from 
patients with sepsis
We observed that NETs were directly induced by heterologous healthy neutrophils incubated 
with platelet-poor plasma taken from a cohort of 54 sepsis patients from 2 ICUs (Figure 1A). 
Typical NETs structures were observed in the wells containing certain septic plasma or 
serum. By contrast, NETs did not form in the wells containing plasma or serum from healthy 
donors (n=20) (Figure 1A), unless co-incubated with 100 nM phorbol myristate acetate 
(PMA), a known positive control for NETs formation. For further validation of patient 
plasma-induced NETs, anti-human neutrophil elastase (NE) and anti-human MPO and 
corresponding FITC and AF700-conjugated secondary antibodies were used and we 
confirmed that the typical features of NETs existed (Figure 1B). Cl-amidine, an inhibitor of 
peptidylarginine deiminase 4 (PAD4) and NETosis, was able to block the plasma or serum-
induced NETs (Figure 1C).  We compared the plasma and serum isolated from blood samples 
taken from the same patients at the same time and found that either plasma or serum could 
induce similar amount of NETs (Figure 1D). Moreover, experiments were also performed 
using patient-specific (n=10) neutrophils incubated with their own plasma to compare with 
the degree of NETs generated by normal donor neutrophils (n=10) and we found no obvious 
difference in NETs formation (Figure 1E).  The degree of NETs formation from patient 
plasma (n=10) was repeatable with neutrophils isolated from different healthy donors (n=10) 
(data not shown). Similarly, there was no exception amongst plasma from different healthy 
volunteers (n=20) with none of them inducing NETs (data not shown).  Differential degrees 
of NETs formation between septic patients (n=54) (Figure 2A) were quantified as a 
percentage (NETs per microscopic field, see Methods) and categorised into 4 groups: Absent 
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(No neutrophils forming NETs per microscopic field) (n=21), Mild (1% to 25%) (n=15); 
Moderate (26% to 50%) (n=10) and Strong (≥50%) (n=8) (Figure 2A). The strong NETs 
induced by patient plasma were equivalent to PMA-induced NETs in healthy samples, 
whereas patient samples with absent NETs were indistinguishable from healthy controls. 
These data indicate that the assay is robust and reliable for quantification. Based on this 
extensive assay validation work we progressed to examine plasma taken from a large cohort 
of ICU patients (n=341) to examine the clinical relevance of NETosis.
Sepsis is the predominant ICU condition associated with NETs formation
In total, 341 patients meeting the inclusion criteria were recruited (Figure E1). The clinical 
characteristics of patients are describ d in Table 1. We found that in 266/341 (78%) patients, 
their plasma could induce NETs formation. In the remaining 75/341 (22%) patients, no NETs 
formation was observed (Table 1). The degree of NETs formation differed between patients: 
170/341 (49.9%) mild, 49/341 (14.4%) moderate and 47/341 (13.8%) strong. The degrees of 
NETs formation were not associated with age, gender or ethnicity (Table 1, P>0.05), but 
strongly associated with primary diseases, in particular a diagnosis of sepsis (Table 1, Figure 
2B). Two-third of moderate and strong NETs formation was induced by plasma from patients 
with sepsis, whilst more than 70% of mild NETs formation was induced by plasma from non-
septic patients. There was no significant correlation between NETs formation and white 
blood cell (R=-0.336, P=0.062) and neutrophil counts (R=-0.309, P=0.114) (Table 2), or with 
other NETs-related markers such as cfDNA (R=-0.134, P=0.864), MPO (R=0.327, P=0.204) 
and DNA-MPO (R=0.158, P=0.982) (Table E2).
Levels of NETs formation in patient plasma strongly predict DIC development
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High levels of NET formation were strongly associated with thrombocytopenia (platelets 
<150 x109/L) (P<0.0001). Over 60% of patients whose plasma induced moderate and strong 
NETs-formation had thrombocytopenia compared to 15.9% in the absent and mild groups (χ2 
test, P<0.001).  Abnormality in PT, activated partial thromboplastin time (aPTT) and 
fibrinogen, as well as D-dimer were also significantly associated with moderate or strong 
NETs formation (P<0.05, compared to mild or absent groups) (Table 2). These parameters 
are collectively indicative of DIC (43) and indeed, DIC development was significantly higher 
in patients with strong (39.4%) and moderate (26.6%) NETs formation compared to mild 
(1.2%) and absent (4.2%) groups (χ2 test, P<0.0001). NETs formation was significantly 
higher in patients with DIC (median: 50.0% [IQR: 25.0%, 88.0%]) compared to those 
without (5.0% [0.0%, 20.0%]) (P<0.0001). To address whether NETs formation on ICU 
admission could predict DIC development post admission, we excluded patients with existing 
DIC on ICU admission (n=28, Table 2). Univariate analysis using the continuous percentages 
of NETs formation demonstrated an odds ratio for DIC was 1.06 (95% CI 1.04-1.08) 
(P<0.0001).  Using categorical data, similar results were obtained, odds ratio 14.52 (95% CI 
3.76-56.06, P<0.0001) for strong and 8.12 (95% CI 2.14-30.77, P=.002) for moderate NETs 
formation groups (Table 3, Figure 2C (left panel)). 
Levels of NETs formation are associated with multi-system organ failure and mortality 
As DIC is associated with development of organ dysfunction and poor outcome, we 
examined the relationship between NETs and multi-organ failure. Assessment with both 
SOFA and modified SOFA (platelet count removed) scores showed that the degree of NETs 
formation was associated with organ injury throughout the study (Table 1). Patients in the 
moderate and strong NETs categories had higher admission SOFA scores (median: 7 [4, 11] 
and 9 [7, 12]) compared to absent and mild groups (SOFA 6 [4, 9] and 6 [3, 8]) (P<0.001).  
Page 43 of 73
For Review Only
11
SOFA scores in the moderate and strong NETs patients remained significantly elevated 
throughout study duration. Furthermore, patients in the strong NETs group had higher 
admission modified SOFA scores (median: 8 [5, 11]) compared to absent (6 [3, 8]), mild (6 
[3, 8]) and moderate groups (6 [3, 10]) (P=0.002), which also remained significant 
throughout the study duration. Patients whose plasma induced strong NETs formation also 
required more cardiovascular support days compared to patients with no NETs (median:10.0 
days [IQR:7.0, 17.0] vs 8.0 [5.0, 11.0]. The mortality rates in both moderate (30.6%) and 
strong (34.0%) NETs formation groups were higher than in absent (12.0%) and mild (15.9%) 
groups (P<0.003). Univariate analysis demonstrated odds ratio of 3.24 for mortality (95% CI 
1.28-8.15) (P=0.013) in the moderate and 3.79 (95% CI 1.51-9.51) (P=0.005) in the strong 
NETs formation group (Table 3). Using continuous percentages of NETs formation data, the 
odds ratio was 1.02 (1.01, 1.03) (P<0.0001). As for other NETs-related assays, there was no 
significant association between cfDNA, MPO or DNA-MPO with mortality (Table 3). 
APACHE II is a commonly used scoring system for severity-of-disease classification. We 
used Spearman’s Rank correlation with continuous percentages of NETs formation data and 
found that NETs-forming capacity was significantly associated with APACHE II scores 
(r=0.442, P=0.013) (Table 1). However, subsequent multivariate analysis demonstrated 
NETs-forming capacity was independently associated with both DIC and mortality after 
adjustment for APACHE II (Table 3, Figure 2C). We found that NETs formation was a 
strong predictor of DIC (AUC=0.851, P<0.001) (Figure 2D) (Table 3). Whilst less strong in 
predicting mortality (AUC=0.656; P<0.001), NETs formation was comparable to both 
APACHE II (AUC=0.683; P<0.001) (Delong’s test vs NETs; P=0.440) and SOFA scores 
(AUC=0.604; P=0.009) (Delong’s test vs NETS; P=0.381) (Figure 2E) (Table 3).
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Anti-IL-8 partially blocks patient plasma from inducing NETs 
Multiple inducers of NETs have been reported, such as IL-1β, IL-6, IL-8, TNFα and 
extracellular histones.  Using our novel assay for NETs formation and cytokine profile 
multiplexes, we found that in our cohort IL-8 was the only cytokine that was significantly 
positively associated with NETs formation (Table E3, Figure 3A), compared to a large 
number of negatively correlated cytokines, including IL-5, IL-9, IL-12, IL-13, IL-17, bFGF, 
GM-CSF and RANTES (Table E3). To functionally investigate if IL-8 was the cytokine 
responsible for NETs formation in our assay, IL-8 was added to normal plasma at relevant 
circulating concentration (100 pg/ml). Upon incubation with healthy neutrophils, NETs 
formation was induced (P=0.008) (Figure 3B). NETs-forming capacities of plasma from 
patients with sepsis (median: 57.5 [47.5, 78.8]) (n=10) were significantly attenuated by a 
functional anti-IL-8 blocking mAb (median: 19 [10.0, 22.5]) (P<0.001), and the clinically 
trialled IL-8 receptor antagonists, Reparixin (median: 7.0 [3.5, 41.3]) (P<0.001) and 
AZD5069 (median: 18.5 [10.0, 28.8]) (P<0.001)  (Figure 3C). Mechanistically, IL-8 
signalling is predominately through Ras/Raf/MAPK pathways (44) (Figure E2), which is 
essential for NETs formation (21). Specific inhibition of MAPK activation using an ERK 
inhibitor (U0126), significantly blocked IL-8 induced NETs formation in normal plasma 
(P=0.005) (Figure 3B) as well NETs-forming capacity of patient plasma (P<0.001) (Figure 
3C). Moreover, ERK phosphorylation induced by patient plasma was also significantly 
reduced by anti-IL-8 mAb treatment (P<0.001) (Figure 3D). Collectively, this supports 
MAPK activation as the major pathway of IL-8-induced NETs formation in patients.
Discussion
We found that NETs formation could be directly induced by patient plasma and was 
associated with clinically relevant information on disease severity, complications and 
outcome in the ICU. The extent of NETs formation on ICU admission was significantly 
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associated with sepsis and independently predicted development of DIC and 28-day 
mortality. The elucidation of IL-8 as a major contributing factor to the NETs-forming 
capacity of patient plasma could bridge important clinical utility with biological plausibility 
on the role of NETs in critical illness. 
NETs have been increasingly recognised in disease pathogenesis since Brinkman et al (12) 
described their ability to trap and kill bacteria in tissue samples from patients with infection. 
As NETosis represents an integral component of the regulated immune response in 
preventing translocation and dissemination of infection (45-47), our results lead us to 
speculate that dysregulated intravascular NETosis may promote platelet trapping and cause 
consumptive coagulopathy to impair end-organ perfusion and provoke MOF. In support of 
this theory, McDonald et al (48) showed NETs-induced intravascular coagulation caused 
widespread microvascular occlusion and MOF in several mice models of sepsis. They also 
found that histones did not promote platelet adhesion to NETs or production of NETs. This 
could be relevant to our findings that demonstrated lack of association between histone levels 
and NETs formation. 
Our findings that moderate to strong NETs formation is commonly observed in septic 
patients with respiratory origin are of particular relevance to patients with pneumonia-
induced Acute Respiratory Distress Syndrome (ARDS) (49). NETs formation in these 
patients is associated with localised alveolar inflammation and with high IL-8 levels within 
bronchoalveolar lavage (BAL) fluid (50).
We believe that a key strength of this study on NETs is the demonstration of how clinically 
relevant information links into mechanistic understanding and identification of therapeutic 
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strategies. Our findings are supported by Yang et al who showed that plasma from septic 
patients were more likely to induce NETs than non-septic patients (51). However, their 
findings were limited to 62 patients with no correlation to clinical outcomes. Compared to 
other NETs-related assays, we found that cfDNA, MPO and MPO-DNA complexes (36, 52-
56) were all poorly associated with admission severity, clinical course and outcomes.  This 
may be due to our assay directly measuring NETs-forming capacity and not being affected by 
NETs degradation rates, factors altering the stability of NETs breakdown products or 
contaminations from neutrophil respiratory burst or death of other types of cells (Figure E2). 
Therefore, our assay is clearly distinct from other NETs-related assays and more accurately 
reflects the degrees of NETs formation in patients. 
A further strength of the assay is its ability to identify the driving factors for NETosis in 
individual patient plasma, including important signalling pathways. This could be used for 
determining potential targets or guiding clinical management as part of precision or 
personalised medicine. We identified IL-8 as an important factor promoting NETosis in some 
patients using this assay and targeting IL-8 by specific inhibitors (Reparixin, AZD5069 and 
anti-IL-8 mAb) could significantly inhibit NETs formation in these patients. Using the same 
assay, we also identified MAPK activation as a major pathway for IL-8 in driving NETosis in 
patients. Using multivariate analysis, IL-8 levels could not independently predict DIC and 
mortality, similar to other reported activating factors for NETs formation (IL-1β, IL-6 and 
TNFα) (Table 3). This is because IL-8 levels are not uniformly elevated in patients and there 
are unknown factors involved which remain to be identified in future studies.
Our assay does not necessarily require isolation of individual patient neutrophils because 
concordant results were obtained when patient plasma was incubated with either homologous 
(patient-specific) or heterologous (healthy individual) neutrophils. This allows flexibility of 
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use in clinical practice with the choice of using patient’s or healthy donor’s neutrophils.  
Since fresh neutrophils are available in most large hospitals with blood banks and this NETs 
assay can be easily categorized by clinical scientists (into Absent, Mild, Moderate or Strong 
groups), it has clear potential to be integrated into routine clinical laboratory practice. Our 
assay was developed in a cohort of septic patients and evaluated in a separate cohort of ICU 
patients. However, limitations of this study are that our results on clinical associations were 
obtained in a single ICU only, but our patient cohort has consistently been representative of 
UK Intensive Care National Audit and Research Centre data. 
In summary, this study demonstrates how a simple, direct approach to understanding NETs-
forming potential in the circulation could be applied clinically to identify patients at risk of 
DIC and poor outcomes in ICU. We have highlighted its potential as a stratification tool on 
ICU admission that could enable administration of early organ support or as a companion 
diagnostic for novel therapies that inhibit NETs formation. As NETs and platelets interact to 
promote intravascular coagulation and its dissemination, there is a highly persuasive rationale 
for targeting NETs in sepsis and DIC. Intravenous DNase has been reported to significantly 
reduce end-organ damage in sepsis models (48). Our finding that IL-8 is a major inducer of 
NETs in many critically ill patients presents an exciting opportunity for more precise 
therapeutic targeting by using our novel assay system with incorporation of IL-8 inhibitors. 
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Figure legends
Figure 1. NETs can be directly induced by plasma or serum from septic patients.
A, Normal healthy human neutrophils were incubated with either normal plasma ± 100 nM PMA 
(n=20) or critically ill patient plasma (n=54) for 4 hours, and extracellular DNA was stained with 
Propidium Iodide (PI). Typical images are presented. B, NETs formation was induced by incubating 
normal healthy human neutrophils with critically ill patient plasma, and extracellular DNA was 
stained with PI, along with human neutrophil elastase (FITC; green) and human myeloperoxidase 
(AF700; blue) using specific antibodies. NETs formation (arrows) was visualized using confocal 
microscopy. C, Pre-incubation of normal neutrophils with Cl-amidine (PAD4 inhibitor) prior to 
treatment with septic patient plasma blocked NETs formation (n=10) (ANOVA; P<.05). D, NETs 
formation was comparable when induced by either plasma (P) or serum (S). Matched normal plasma 
(n=20) and serum (n=20) did not induce NETs formation when incubated with normal healthy 
neutrophils, unless incubated with 100 nM PMA (n=3). There were no significant difference between 
septic patient plasma (n=10) and serum (n=10) in inducing NETs formation (ANOVA test; P>.05). E, 
Incubating either normal neutrophils or septic patient neutrophils, with matched septic patient plasma 
induced comparable NETs (n=10) (ANOVA; P<.05).
Figure 2. The degree of NETs formation is associated with sepsis and poor clinical outcomes.
A, NETs formed was categorised into 4 groups based on the percentage of neutrophils forming NETs 
per microscopic field which were visualized using fluorescent microscopy and PI staining. Typical 
images are shown. B, NETs formation was associated with an admission diagnosis of sepsis. Plasma 
from normal healthy donors did not induce NETs formation when incubated with normal neutrophils 
(n=20). When patients (n=341) were stratified based on admission diagnosis into those without 
(n=198) and those with sepsis (n=143), NETs formation was significantly elevated in those patients 
with sepsis (ANOVA; P<.05). C, Multivariable analysis of crude and adjusted odds ratios (with 
patients adjusted for APACHE II scores) demonstrated that NETs were an independent predictor of 
DIC development (left panel) and 28-day mortality (right panel) (n=341). Receiver Operating 
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Characteristic (ROC) curves for measuring the NETs-forming capacity of patient plasma on ICU 
admission, for predicting DIC development (D) and mortality (E) (n=341).
Figure 3. IL-8 contributes to the NETs-forming capacity of critically ill patient plasma, which is 
partially blocked by anti-IL-8 and anti-MAPK treatment.
A, Quantification of circulating factors known to stimulate NETs formation (Histones, IL-1β, IL-6, 
IL-8 and TNFα) in patient plasma on ICU admission, demonstrated that IL-8 was elevated in patients 
that were able to induce NETs (ANOVA; P<.05) (n=341). B, Incubation of 100 pg/ml IL-8 in normal 
plasma with normal healthy neutrophils for 4 hours induced NETs formation compared to normal 
plasma alone (n=10), which was blocked by inhibiting MAPK activation with U0126 (ERKi) (n=3) 
(ANOVA; P<.05). C, Pre-incubation of normal neutrophils with either anti-IL-8 mAb (α-IL-8) 
(n=10), Reparixin (REP) (n=10), AZD5069 (n=10) or MAPK inhibitor U0126 (ERKi) (n=6) prior to 
treatment with septic patient plasma partially blocked NETs formation (ANOVA; P<.05). D, Western 
blot analysis of ERK activation (pERK/ERK ratio) in normal neutrophils incubated for 15 mins with 
septic patient plasma pre-incubated without (UT) or with anti-IL-8 mAb (α-IL-8) (n=3) (ANOVA; 
P<.05). 
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-.643
-.677
-.639
241.0 [173.0-320.0]
218.5 [173.3-303.3]
236.0 [170.0-287.0]
222.0 [165.5-303.8]
217.5 [175.5-331.0]
223.0 [163.0-306.8]
214.0 [163.0-301.0]
225.0 [166.3-309.5]
135.0 [72.0-222.0]  †,‡
136.0 [64.0-233.3]  †,‡
113.5 [48.8-203.3]  †,‡
99.0 [42.0-205.8]  †,‡
106.0 [61.0-166.0]  †,‡
91.5 [53.0-150.8]  †,‡
69.0 [39.5-131.0]  †,‡
82.0 [42.0-118.0]  †,‡
<.0001
<.0001
<.0001
<.0001
C
oagulation param
eters
PT (seconds), M
edian [IQ
R
]
             A
dm
ission
             24 hrs post adm
ission
             48 hrs post adm
ission
             72 hrs post adm
ission 
15.0 [13.2-18.1]
14.6 [13.0-17.2]
13.9 [12.5-16.0]
13.7 [12.3-15.2]
.435
.399
.292
-.126
14.8 [13.6-16.8]
14.5 [13.2-16.8]
14.0 [12.8-15.7]
13.9 [12.8-16.2]
14.6 [12.9-16.6]
14.4 [12.9-16.5]
13.8 [12.3-15.7]
13.6 [12.2-14.9]
15.4 [13.3-19.2]
14.7 [13.3-18.5]
13.9 [12.1-18.1]
13.9 [11.7-16.9]
17.7 [13.3-21.3]  †,‡
16.4 [12.8-20.4]
14.7 [12.1-17.1]
13.7 [12.5-15.4]
.014
.332
.706
.446
aPTT (seconds), M
edian [IQ
R
]
             A
dm
ission
             24 hrs post adm
ission
             48 hrs post adm
ission
             72 hrs post adm
ission 
32.3 [28.6-38.4]
33.3 [29.0-39.6]
32.1 [28.6-38.3]
31.5 [28.4-36.5]
.621
.553
.581
.550
30.3 [27.3-35.5]
31.9 [28.2-35.9]
30.6 [28.4-35.5]
30.5 [28.3-34.0]
31.4 [28.0-37.0]
32.8 [28.9-38.6]
31.5 [28.4-37.3]
31.0 [28.3-35.8]
35.8 [30.2-44.2]  †,‡
35.7 [30.6-43.0]  †
34.5 [30.5-42.6]  †,‡
34.4 [29.8-41.6]  †,‡
40.2 [32.8-51.4]  †,‡
39.4 [31.8-45.5]  †,‡
37.5 [30.4-43.9]  †,‡
34.7 [29.0-39.5]  †,‡
<.0001
<.0001
<.0001
.004
Fibrinogen (g/L), M
edian [IQ
R
]
             A
dm
ission
             24 hrs post adm
ission
             48 hrs post adm
ission
             72 hrs post adm
ission 
3.8 [2.5-5.0]
4.1 [2.9-5.2]
4.4 [3.4-5.4]
4.6 [3.5-5.6]
-.565
-.568
-.560
-.531
4.5 [3.0-5.4]
4.5 [3.2-5.5]
4.6 [4.0-5.8]
4.8 [3.9-6.0]
4.0 [3.0-5.1]
4.3 [3.3-5.4]
4.6 [3.5-5.7]
4.8 [3.8-5.9]
3.4 [2.1-4.9]  †
3.7 [2.6-5.2]  †,‡
4.1 [2.1-5.1]  †,‡
3.6 [2.2-5.2]  †,‡
2.3 [1.5-3.5]  †,‡,§
2.7 [1.8-3.8]  †,‡,§
3.1 [2.3-4.4]  †,‡
3.7 [2.5-5.0]  †,‡
<.0001
<.0001
<.0001
<.0001
D
-dim
er (ng/m
l), M
edian [IQ
R
]
             A
dm
ission
             24 hrs post adm
ission
             48 hrs post adm
ission
             72 hrs post adm
ission
4073.5 [2054.8-7759.4]
4485.0 [2147.0-8737.0]
5044.1 [2175.9-7394.8]
4931.0 [2386.5-7762.7]
.377
.214
.333
.319
3788.0 [1925.3-6335.0]
4687.5 [2941.0-10879.3]
4145.0 [2783.0-10341.0]
4407.0 [2211.0, 9089.0]
3756.2 [1865.0-6284.8]
4975.8 [1227.0-7251.2]
5150.1 [1803.3-7252.7]
4743.0 [2952.0-6919.0]
5549.3 [1877.6-12276.0]
5064.0 [2015.0-7022.0]
4504.5 [2252.3-9001.2]
5275.9 [2733.2-14048.1]
6261.0 [2464.4-15527.6]  †,‡
5791.0 [3809.0-15167.0]
4729.0 [2784.0-14336.9]
5437.0 [1563.5-19292.0]
.143
.494
.888
.983
Total D
IC
 (n) [%
]
58 [17.0%
]
-
8 [10.7%
]
7 [6.7%
]
16 [32.7%
]  †,‡
27 [57.4%
]  †,‡,§
<.0001
Tim
e to develop D
IC
 (n) [%
]
             A
dm
ission
             24 hrs post adm
ission
             48 hrs post adm
ission
             72 hrs post adm
ission 
28 [8.2%
]
13 [3.8%
]
10 [2.9%
]
7 [2.1%
]
----
5 [6.7%
]
0 [0.0%
]
3 [4.0%
]
0 [0.0%
]
5 [2.9%
]
1 [0.6%
]
1 [0.6%
]
0 [0.0%
]
4 [8.2%
]
5 [10.2%
] †,‡
2 [4.1%
]
5 [10.2%
] †
14 [30.0%
] †,‡,§
7 [14.9%
] †,‡
4 [8.5%
] ‡
2 [4.3%
]
<.0001
<.0001
.001
<.0001
D
eveloped D
IC
 ≥24 hrs post adm
ission (n) [%
]
30 [8.8%
]
-
3 [4.2%
]
2 [1.2%
]
12 [26.6%
] †,‡
13 [39.4%
] †,‡
<.0001
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3
T
able 2. Peripheral blood m
easurem
ents of absent, m
ild, m
oderate and strong N
ETs form
ation in IC
U
 patients
* P value for com
parisons of vs m
ild vs m
oderate vs strong N
ETs patients collectively. Perform
ed using K
ruskall-W
allis test for continuous 
variables and C
hi-squared test for categorical variables. † Significant vs absent N
ETs patients.  ‡  Significant vs m
ild N
ETs patients.  §  Significant 
vs m
oderate N
ETs patients.  R
 correlation w
ith percentage N
ETs perform
ed using Spearm
an’s rank.
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4
C
rude O
dds ratio
P value *
A
djusted odds ratio
[A
PA
C
H
E
II]
P value
†
A
U
C
P value ‡
D
IC
A
bsent N
ETs
R
EF
R
EF
M
ild N
ETs
0.274 [0.045-1.677]
.161
0.248 [0.039-1.560]
.137
-
-
M
oderate N
ETs
8.121 [2.143-30.770]
.002
7.176 [1.765-29.177]
.006
-
-
Strong N
ETs
14.517 [3.759-56.057]
<.0001
13.035 [3.157-53.829]
<.0001
-
-
N
ETs [%
]
1.059 [1.041-1.078]
<.0001
1.058 [1.039-1.078]
<.0001
0.851
<.0001
cfD
N
A
1.001 [1.000-1.001]
.060
1.001 [1.000-1.001]
.118
0.607
.324
M
PO
1.001 [0.997-1.004]
.664
1.001 [0.997-1.005]
.689
0.609
.236
D
N
A
-M
PO
17.428 [1.976-153.679]
.010
9.780 [0.972-98.424]
.053
0.713
.013
IL
-1β
0.993 [0.923-1.068]
.845
0.999 [0.920-1.084]
.973
0.588
.272
IL-6
1.000 [1.000-1.000]
.113
1.000 [1.000-1.000]
.139
0.546
.499
T
N
F
α
0.999 [0.994-1.003]
.501
0.999 [0.995-1.003]
.593
0.658
.044
IL-8
1.000 [1.000-1.000]
.049
1.000 [1.000-1.001]
.083
0.666
.002
A
PA
C
H
EII
1.144 [1.084-1.208]
<.0001
-
-
0.753
<.0001
SO
FA
 score
1.435 [1.274-1.616]
<.0001
-
-
0.837
<.0001
M
ortality
A
bsent N
ETs
R
EF
R
EF
M
ild N
ETs
1.385 [0.617-3.109]
.430
1.370 [0.601-3.125]
.454
-
-
M
oderate N
ETs
3.235 [1.284-8.152]
.013
2.889 [1.114-7.494]
.029
-
-
Strong N
ETs
3.785 [1.506-9.511]
.005
2.995 [1.162-7.720]
.023
-
-
N
ETs [%
]
1.020 [1.010-1.030]
<.0001
1.016 [1.006-1.026]
.002
0.851
<.0001
cfD
N
A
1.000 [1.000-1.000]
.232
1.000 [1.000-1.000]
.532
0.607
.324
M
PO
0.998 [.0994-1.002]
.353
0.998 [0.993-1.002]
.261
0.609
.236
D
N
A
-M
PO
2.005 [0.430-9.359]
.376
1.432 [0.286-7.161]
.662
0.713
.013
IL
-1β
1.008 [.0981-1.035]
.570
1.003 [1.011-1.119]
.804
0.501
.984
IL-6
1.000 [1.000-1.000]
.907
1.000 [1.000-1.000]
.904
0.596
.064
T
N
F
α
0.999 [0.997-1.002]
.671
0.999 [0.996-1.002]
.598
0.511
.846
IL-8
1.000 [1.000-1.000]
.380
1.000 [1.000-1.000]
.563
0.574
.141
A
PA
C
H
EII
1.087 [1.047-1.128]
<.0001
-
-
0.683
<.0001
SO
FA
 score
1.087 [1.017-1.162]
.014
-
-
0.604
.009
T
able 3. N
ETs form
ation is an independent predictor of D
IC
 and m
ortality in critically ill patients
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5
* P value for crude odds ratio to predict D
IC
 and m
ortality. † P value for adjusted odds ratios to predict D
IC
 and m
ortality in a m
ultivariable 
analysis (w
ith patients adjusted for A
PA
C
H
E II scores).  ‡ P value for R
O
C
 analysis to predict D
IC
 and m
ortality.
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Figure￿2
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U
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O
nline D
ata Supplem
ent
A
 N
ovel A
ssay for N
eutrophil E
xtracellular T
raps (N
E
T
s) Form
ation Independently Predicts D
issem
inated Intravascular C
oagulation and M
ortality 
in C
ritically Ill Patients 
Short running head: M
onitoring N
ETosis in critical illness
Sim
on T A
bram
s, PhD
1, B
en M
orton M
B
C
hB
, M
D
2,3, Y
asir A
lham
di, M
B
C
hB
, PhD
1, M
ohm
ad A
lsabani 1,
Steven Lane, PhD
4, Ingeborg D
 W
elters, PhD
5,6, G
uozheng W
ang, M
D
, PhD
1 and C
heng-H
ock Toh, M
D
1,7
eM
ethods
Patient blood sam
ple collection and m
easurem
ent
U
pon IC
U
 adm
ission, surplus blood sam
ples w
ere collected daily from
 all patients for the first 96 hours (4 sam
ples per patient: adm
ission, 24 hours, 48 hours 
and 72 hours post-adm
ission).  Plasm
a w
as prepared by draw
ing peripheral blood into citrated vacutainers (4.5 m
l 0.109 M
 + buffered sodium
 citrate 3.2%
, 
B
ecton D
ickinson, Plym
outh, U
K
) and centrifuged for 20 m
inutes at 2600xg and 20°C
. The resulting plasm
a supernatant w
as separated and aliquots stored at 
-80
oC
. In som
e patients, m
atched sera w
ere also isolated and stored at -80°C
.W
hole blood platelet, w
hite blood cell and neutrophil counts w
ere m
easured 
using a B
eckm
an C
oulter D
xH
800, throm
bocytopaenia w
as m
icroscopically verified. Prothrom
bin tim
e (PT), activated partial throm
boplastin tim
e (A
PTT), 
fibrinogen levels and D
-dim
ers w
ere m
easured using standard protocols in the coagulation laboratory of the R
oyal Liverpool U
niversity H
ospital using an 
A
C
L TO
P
®
 700 analyser (W
erfen Ltd, U
K
). A
 panel of 27 cytokines, chem
okines and angiogenic factors (G
eneral activation m
arkers: Interleukin (IL
)-1β,IL
-
1ra, IL-2, T
N
F
α, IL-6, IL-15; C
hem
okines: IL-8, IP-10, M
C
P-1, M
IP-1a, M
IP-1b, R
A
N
TES; T cell-related: IL-4, IL-5, IL-9, IL-10, IL-12 (p70), IL-13, IL-
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17, Eotaxin, IN
F
γ; B
one m
arrow
-derived: IL-7, G
M
-C
SF, G
-C
SF; A
ngiogenic factors and endothelial m
itogens: bFG
F, PD
G
F-bb, V
EG
F) w
ere m
easured by 
M
ultiPlex (B
ioR
ad) in the plasm
a of norm
al donors and critically ill patients upon IC
U
 adm
ission, using a B
io-Plex 100 according to m
anufacturers’ 
instructions.  
N
eutrophil isolation
C
itrated blood w
as draw
n from
 healthy donors follow
ing w
ritten inform
ed consent according to protocol approved by Liverpool U
niversity Interventional 
Ethical C
om
m
ittee (R
ef: R
ETH
000685). N
eutrophils w
ere purified using tw
o-step gradient centrifugation. Leukocytes w
ere isolated using H
istopaque®
-1077 
(Sigm
a-A
ldrich, U
K
) and further purified using a Percoll (Sigm
a-A
ldrich) gradient to isolate neutrophils (>90%
 purity).
N
E
T
s specific neutralization
To exam
ine the role of interleukin 8 (IL-8) in N
ETs form
ation, norm
al plasm
a w
as supplem
ented w
ith IL-8 (100 pg/m
l) and incubated w
ith norm
al 
neutrophils for 4 hours prior to fixation and staining.  N
eutrophils w
ere also pre-incubated for 10 m
inutes w
ith IL-8 inhibitors: anti-IL-8 m
A
b (R
&
D
 System
s) 
(1 µg/m
l), C
l-am
idine (C
am
bridge biolabs) (10 µM
), R
eparixin (D
em
pé) (250 µg/m
l) or A
ZD
5069 (A
straZeneca) (10 nM
), or a M
A
PK
 signalling inhibitor: 
U
0126 (Sigm
a) (50 µM
) prior to adding plasm
a. 
C
om
parator N
E
T
s assays
C
irculating histones levels w
ere determ
ined by W
estern blot, according to our previous publications.(1-3)  C
ell free D
N
A
 (cfD
N
A
) w
as fluorescently 
determ
ined using SY
TO
X
 green, as previously described.(4) B
riefly, 25µl patient plasm
a w
as diluted in a final volum
e of 100 µl and incubated w
ith SY
TO
X
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green (2 µM
 final concentration). cfD
N
A
 w
as then determ
ined using a fluorescent plater reader (Ex:488nm
/Em
:523nm
) using know
n concentrations of 
genom
ic D
N
A
 as standards. C
irculating M
yeloperoxidase (M
PO
) (Therm
oFisher) w
ere m
easured by ELISA
 according to the m
anufacturer’s instructions. 
C
irculating M
PO
-D
N
A
 com
plex levels w
ere determ
ined using by ELISA
 using an anti-M
PO
 (SantaC
ruz B
iotech) capture antibody and anti-dsD
N
A
 antibody 
(R
O
C
H
E) as a detector. C
itrullinated H
istone 3 (C
it-H
3) w
as determ
ined in patient plasm
a by W
estern blot using a prim
ary antibody against C
it-H
3 (A
bcam
), 
data w
ere not included due to non-specificity of the antibody.
W
estern blot analysis of E
R
K
 activation
W
estern blot analysis w
as perform
ed on norm
al healthy neutrophils treated w
ith plasm
a. To investigate the effect of IL-8 treatm
ent on the activation of ER
K
 
neutrophils w
ere treated for 0, 15, 30, 45 and 60 m
inutes w
ith norm
al plasm
a supplem
ented w
ith IL-8 (100 pg/m
l). To establish the role of circulating IL-8 
patients in activating ER
K
, norm
al heatly neutrophils w
ere incubated w
ithout or w
ith pre-treatm
ent w
ith anti-IL-8 m
A
b (1 µg/m
l), prior to treatm
ent w
ith 
septic patient plasm
 for 15 m
inutes. Follow
ing treatm
ent, sam
ples w
ere lysed and separated by SD
S-PA
G
E follow
ed by transfer onto PV
D
F m
em
brane. 
Follow
ing blocking, m
em
branes w
ere probed w
ith 1:1000 anti-pER
K
 antibody (Santa C
ruz) overnight and 1:10,000 anti-m
ouse secondary antibody for 45 
m
ins. B
ands w
ere visualised using EC
L (Enhanced C
hem
ilum
inescence). To ensure equal loading, m
em
branes w
ere stripped using stripping buffer for 30 
m
ins at 50°C
 and blocked. M
em
branes w
ere probed w
ith 1:1000 anti-ER
K
 antibody (Santa C
ruz) overnight and 1:10,000 anti-rabbit secondary antibody for 
45 m
ins. B
ands w
ere visualised using EC
L and densitom
etry perform
ed to determ
ine pER
K
/ER
K
 ratio.
M
ultivariate logistical regression analysis
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Prior to construction of the m
ultivariate m
odel, w
e selected variables that could plausibly be associated w
ith D
IC
 and m
ortality. These variables w
ere tested 
in univariate analysis to determ
ine their association as are displayed in Table E1. For the m
ultivariate, analysis w
e selected variables independent from
 one 
another w
ith a univariate analysis p value of less than 0.1. Follow
ing on from
 this, w
e constructed the final m
ultivariate m
odel using a standard stepw
ise 
approach, sequentially rem
oving variables w
ith a p value of m
ore than 0.1.
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C
rude O
dds ratio
P value *
D
IC
Initial diagnosis
Sepsis
R
EF
C
ardiovascular
0.000 [0.000-0.000]
.998
C
N
S
0.000 [0.000-0.000]
.998
G
astro
0.258 [0.058-1.151]
.076
R
enal
0.000 [0.000-0.000]
.999
R
espiratory
0.087 [0.019-0.661]
.018
Traum
a
0.222 [0.064-0.770]
.018
H
ypotension
2.220 [1.001-4.923]
.050
A
R
D
S (P/F)
1.000 [0.996-1.003]
.945
A
PA
C
H
E
II
1.144 [1.084-1.208]
<.0001
B
acteraem
ia
7.625 [3.027-19.205]
<.0001
Source of infection
N
o infection
R
EF
R
espiratory
7.843 [2.625-23.431]
<.0001
A
bdom
en
5.337 [1.702-16.736]
.004
N
euro
11.091 [2.724-45.150]
.001
O
ther
10.893 [2.953-40.183]
<.0001
IL
-8
1.000 [1.000-1.000]
.049
A
ge
0.988 [0.967-1.009]
.255
G
ender
0.538 [0.249-1.165]
.116
M
ortality
Initial diagnosis
Sepsis
R
EF
C
ardiovascular
1.036 [0.442-2.427]
.935
C
N
S
0.184 [0.024-1.442]
.107
G
astro
0.461 [0.167-1.273]
.135
R
enal
0.000 [0.000-0.000]
.999
R
espiratory
0.395 [0.155-1.003]
.051
Traum
a
0.417 [0.182-0.957]
.039
H
ypotension
1.113 [0.641-1.933]
.704
A
R
D
S (P/F)
0.998 [0.996-1.001]
.204
A
PA
C
H
E
II
1.087 [1.047-1.128]
<.0001
B
acteraem
ia
2.109 [1.228-3.623]
.007
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T
able E
1. U
nivariate analysis for the prediction of D
IC
 and m
ortality.
To construct the m
ultivariate m
odel an independent variable w
as included if univariate analysis indicated a p<0.1 and gender (convention). N
ETosis, IL-8, 
A
PA
C
H
EII, source of infection (categorical) and gender w
ithin the initial m
ultivariate analysis and rem
oved non-significant variables (p>0.1) in a stepw
ise 
m
ethod until all rem
aining variables w
ere significant. W
e perform
ed m
ultivariate analysis w
ith the dependent variables of D
IC
 and M
ortality. Stepw
ise 
regression for D
IC
, IL-8 (p=0.117), source of infection (p = 0.825, 0.361, 0.679 and 0.936 respectively) and gender (p=0.175) w
ere rem
oved. Stepw
ise 
regression for m
ortality, IL-8 (p=0.984), source of infection (p = 0.814, 0.348, 0.535 and 0.510 respectively) and gender (p=0.826) w
ere rem
oved. O
ur final 
m
odels for predicting D
IC
 and m
ortality are adjusted for A
PA
C
H
E II (Table 3).
* P value for crude odds ratio to predict D
IC
 and m
ortality.
Source of infection
N
o infection
R
EF
R
espiratory
2.914 [1.421-5.973]
.004
A
bdom
en
1.457 [0.651-3.233]
.355
N
euro
1.166 [0.317-4.280]
.817
O
ther
2.914 [1.194-7.109]
.019
IL
-8
1.000 [1.000-1.000]
.380
A
ge
1.014 [0.997-1.031]
.102
G
ender
0.850 [0.498-1.451]
.551
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T
able E
2. C
irculating N
ETs-related m
arkers in absent, m
ild, m
oderate and strong N
ETs form
ation in IC
U
 patients
* P value for com
parisons of absent vs m
ild vs m
oderate vs strong N
ETs patients collectively. Perform
ed using K
ruskall-W
allis test for continuous variables 
and C
hi-squared test for categorical variables. † Significant vs norm
al controls. ‡ Significant vs absent N
ETs patients.  § Significant vs m
ild N
ETs patients.  R
 
correlation w
ith percentage N
ETs perform
ed using Spearm
an’s rank.
N
orm
al
C
orrelation
(R
 value)
A
bsent
N
E
T
s
M
ild
N
E
T
s
M
oderate
N
E
T
s
Strong
N
E
T
s
P value
*
Total num
ber (n)
75
170
49
47
N
E
T
s-related m
arkers
cfD
N
A
 (ng/m
l), M
edian [IQ
R
]
245.70 [154.63-443.21]
-.134
617.9 [378.8-971.3] †
521.8 [237.6-1015.8]
530.3 [367.9-990.5]
496.0 [316.8-1237.4]
.864
M
PO
 (ng/m
l), M
edian [IQ
R
]
12.40 [4.55-35.39]
.327
97.4 [36.8-180.8]  †
65.5 [39.4-96.1]  †
154.4 [51.7-312.2]  †, §
101.1 [33.1-192.2]  ‡
.204
D
N
A
-M
PO
 (A
U
), M
edian [IQ
R
]
0.97 [0.89-1.11]
.158
0.89 [0.83-1.16]
0.96 [0.84-1.19]
0.94 [0.84-1.08]
0.92 [0.82-1.10]
.982
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N
orm
al
C
orrelation 
(R
 value)
A
bsent
N
E
T
s
M
ild
N
E
T
s
M
oderate
N
E
T
s
Strong
N
E
T
s
P value
*
Total num
ber (n)
75
170
49
47
G
eneral activation
IL
-1β (pg/m
l), M
edian [IQ
R
]
5.65 [4.65-6.34]
-.293
5.86 [3.61-8.98]
5.51 [3.33-7.88]
4.95 [3.72-9.37]
4.51 [2.88-8.62]
.773
IL-1ra (pg/m
l), M
edian [IQ
R
]
177.58 [153.24-247.02]
-.286
1098.86 [318.56-6046.29] †
1025.10 [270.46-5705.21]  †
443.08 [190.69-2598.12]  †
522.78 [170.83-5580.57]  †
.485
IL-2 (pg/m
l), M
edian [IQ
R
]
0.00 [0.00-3.38]
-.297
0.00 [0.00-7.78]
0.00 [0.00-3.53]
0.00 [0.00-0.00]  §
0.00 [0.00-4.23]
.176
T
N
F
α (pg/m
l), M
edian [IQ
R
]
96.50 [61.56-125.53]
-.265
113.80 [60.41-158.11]
70.51 [51.83-138.10]
94.47 [43.99-150.35]
100.57 [40.56-171.85]
.663
IL-6 (pg/m
l), M
edian [IQ
R
]
15.15 [12.36-19.52]
.265
161.99 [69.65-1123.54]
445.30 [61.09-1216.67]  †
146.80 [40.43-608.98]  †
343.86 [85.97-2449.15]  †, ll
.177
IL-15 (pg/m
l), M
edian [IQ
R
]
0.00 [0.00-12.59]
-.241
12.53 [0.00-79.01]
20.91 [0.00-45.54]  †
0.00 [0.00-32.41]
24.55 [0.00-55.59]  †
.279
C
hem
okines
IL-8 (pg/m
l), M
edian [IQ
R
]
29.31 [26.74-55.93]
.529
63.27 [39.28-143.31]  †
128.89 [48.47-255.64]  †
114.36 [52.76-314.29]  †
127.53 [73.50-331.65]  †, ‡
.069
IP-10 (pg/m
l), M
edian [IQ
R
]
540.68 [379.22-656.62]
.221
1118.65 [668.75-6877.97]  †
1037.15 [527.40-1914.35]  †
1632.67 [494.98-7669.59]  †
1077.73 [683.36-2954.90]  †
.529
M
C
P-1 (pg/m
l), M
edian [IQ
R
]
4.90 [0.00-19.81]
.235
58.00 [22.67-167.01]  †
87.17 [27.21-200.48]  †
31.54 [2.35-181.35]  §
112.28 [33.96-237.29]  †
.172
M
IP-1a (pg/m
l), M
edian [IQ
R
]
5.93 [4.14-7.62]
-.230
5.14 [2.98-7.81]
4.37 [2.98-6.09]
4.92 [3.33-7.61]
4.45 [2.36-6.47]
.768
M
IP-1b (pg/m
l), M
edian [IQ
R
]
23.64 [14.72-34.15]
-.307
92.75 [71.93-240.96]  †
100.55 [61.86-172.69]  †
96.33 [68.23-164.86]  †
91.12 [60.66-139.34]  †
.649
R
A
N
TES (pg/m
l), M
edian [IQ
R
]
3142.25 [1278.65-3558.20]
-.560
4690.15 [2372.52-6221.61]
5085.97 [3566.83-7098.21]  †
3164.76 [1716.22-4301.35]  §
2905.09 [14445.22-4311.39]  ‡, §
<.0001
T
 cell-related
IL-4 (pg/m
l), M
edian [IQ
R
]
6.19 [5.74-7.23]
-.463
6.36 [4.65-8.42]
6.90 [5.30-8.08]
5.86 [4.12-7.94]
5.00 [3.19-7.60]  §
.126
IL-5 (pg/m
l), M
edian [IQ
R
]
20.18 [8.99-21.52]
-.608
11.36 [4.79-16.28]  †
10.55 [4.79-15.18]  †
9.08 [1.90-15.29]  †
1.63 [0.00-6.40]  †, ‡, §, ll
.001
IL-9 (pg/m
l), M
edian [IQ
R
]
17.54 [14.05-44.76]
-.476
56.71 [23.00-94.63]  †
47.95 [26.42-84.40]  †
30.53 [21.40-49.81]  §
28.25 [18.08-59.16]  ‡, §
.043
IL-10 (pg/m
l), M
edian [IQ
R
]
17.81 [12.79-26.34]
-.266
31.99 [17.63-136.96]
33.80 [20.01-43.01]  †
21.20 [13.85-74.45]
37.54 [16.94-79.03]
.432
IL-12 (p70) (pg/m
l), M
edian [IQ
R
]
8.88 [2.73-26.86]
-.576
16.05 [7.46-21.45]
13.95 [9.04-18.96]
11.09 [6.10-19.36]
7.74 [3.10-13.60]  ‡, §
.004
IL-13 (pg/m
l), M
edian [IQ
R
]
8.62 [3.77-13.82]
-.528
5.31 [2.14-7.81]
5.15 [3.91-9.85]
5.31 [2.19-8.98]
2.71 [0.11-4.39]  †, §, ll
.009
IL-17 (pg/m
l), M
edian [IQ
R
]
29.13 [7.53-33.46]
-.512
39.07 [26.70-71.62]
44.29 [21.38-71.00]  †
25.41 [15.91-60.50]
21.74 [5.07-39.31]  ‡, §
.007
Eotaxin (pg/m
l), M
edian [IQ
R
]
87.97 [62.29-113.57]
-.200
95.45 [58.38-127.69]
93.91 [65.52-123.15]
81.49 [58.91-133.11]
91.30 [61.74-119.68]
.960
IN
F
γ (pg/m
l), M
edian [IQ
R
]
162.57 [124.31-201.07]
-.369
162.97 [119.33-269.09]
146.16 [122.53-205.00]
163.95 [119.55-241.74]
134.46 [79.72-223.60]
.415
B
one m
arrow
-derived
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3. C
irculating cytokine levels in absent, m
ild, m
oderate and strong N
ETs form
ation in patients on IC
U
 adm
ission.
* P value for com
parisons of absent vs m
ild vs m
oderate vs strong N
ETs-form
ation in IC
U
 patients. Perform
ed using K
ruskall-W
allis test for continuous 
variables and C
hi-squared test for categorical variables. † Significant vs N
orm
al controls. ‡  Significant vs absent N
ETs patients.  §  Significant vs m
ild N
ETs 
patients. ll Significant vs m
oderate N
ETs patients.  R
 correlation w
ith percentage N
ETs in patient sam
ples perform
ed using Spearm
an’s rank.
IL-7 (pg/m
l), M
edian [IQ
R
]
22.05 [15.07-29.12]
-.223
17.72 [8.73-22.44]
14.91 [8.57-23.56]
16.36 [7.48-23.51]
14.38 [5.43-30.81]
.973
G
M
-C
SF (pg/m
l), M
edian [IQ
R
]
0.00 [0.00-0.00]
-.365
90.08 [0.00-177.10]  †
66.70 [31.51-143.91]  †
0.00 [0.00-55.59]  ‡, §
51.78 [0.00-143.58]  †, ll
.006
G
-C
SF (pg/m
l), M
edian [IQ
R
]
112.28 [108.85-139.09]
-.077
152.70 [112.77-318.01]
226.19 [90.74-821.29]
117.67 [79.94-364.42]
178.59 [76.70-738.95]
.509
A
ngiogenic factors and endothelial m
itogens
bFG
F (pg/m
l), M
edian [IQ
R
]
32.85 [10.92-153.67]
-.529
64.80 [50.95-92.73]
77.01 [51.64-99.15]
41.55 [18.20-62.48]  ‡, §
48.86 [22.89-76.03]  ‡, §
<.0001
PD
G
F-bb (pg/m
l), M
edian [IQ
R
]
636.75 [152.18-863.18]
-.458
528.68 [147.68-1308.47]
662.11 [284.66-888.55]
455.37 [138.82-825.18]
324.95 [122.72-653.54]  §
.196
V
EG
F (pg/m
l), M
edian [IQ
R
]
11.99 [2.21-62.04]
-.464
78.93 [29.29-112.58]  †
65.28 [35.64-107.89]  †
54.48 [20.10-98.32]  †
49.91 [14.05-82.45]  §
.105
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Figure E1. CONSORT diagram illustrating patientsí initial recruitment, excluded groups and final 
study number
Total patients initially recruited
N=589
Non-availability of sufficient  sample
for analysis
N=98
ICU readmission
N=26
Transfer from other ICUs
N=21
Non-availability of coagulation 
measurements and/or whole blood counts
N=66
Patients with pre-existing cause 
of neutropenia
N=23
Patients finally enrolled in study
N=341
Patients receiving intravenous heparin
N=14
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